Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) is now available.
Hansoh Pharmaceutical Group Company Limited announced that its self-developed B7-H4-targeted antibody-drug conjugate, HS-20089, has been granted Breakthrough-Therapy-Designated status by China’s National Medical Products Administration. This designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The product is in Phase III clinical trials in China and has an exclusive worldwide license agreement with GlaxoSmithKline for development and commercialization outside Greater China, indicating significant potential for global market expansion.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company specializes in antibody-drug conjugates and other pharmaceutical products targeting various cancers and diseases.
YTD Price Performance: 39.47%
Average Trading Volume: 10,455,278
Technical Sentiment Signal: Sell
Current Market Cap: HK$143.3B
See more data about 3692 stock on TipRanks’ Stock Analysis page.